打开APP

为何纽约一直未能成为生物医药产业中心?

  1. 生物医药产业
  2. 纽约

来源:生物谷 2014-07-18 11:33

为何纽约一直未能成为生物医药产业中心?

2014年7月18日讯 /生物谷BIOON/ --作为美国乃至世界上最大的经济中心之一,纽约拥有最多的财团。同时一些重要的医药产业管理部门也坐落在这个城市。然而纽约却一直没有如其政府所愿成为能与波士顿、旧金山比肩的生物医药产业中心。

造成这一现象的重要原因是地价过高。2006年,纽约市政府开始了一项布鲁克林计划,这一计划主要是为了吸引生物医药企业落户纽约。然而八年过去了,这一计划收效甚微。作为一种技术密集型产业,生物医药产业必须依托当地强大的学术机构,然而纽约周围的学术机构如康奈尔大学医学院、哥伦比亚大学医学院都位于较远的曼哈顿地区,这一无形中令生物医药公司望而却步。因此作为世界金融中心的纽约要想成为比肩波士顿、旧金山的生物医药中心,仍有很长路要走。(生物谷Bioon.com)

详细英文报道:

New York City is the center of the world's largest economy, home to some banner medical institutions and a hotbed of global financiers. But the city has never evolved into the biotech hotbed local leaders have hoped to see, a failure largely due to one of its inescapable traits: high rent.

The Wall Street Journal takes a deep look at the issue, spotlighting a $53.4 million Brooklyn project as an illustrative example. City and state officials set out to build a sweeping biotech space in the Brooklyn Army Terminal, planning to create 1,000 jobs and seed the breeding ground that would finally usher in a life sciences scene to rival Boston and San Francisco. Now, 8 years later, BioBAT is up and running, but its 9 stories remain mostly empty, according to WSJ.

BioBAT's trouble recruiting startups and researchers is, in part, one of logistics. Biotech startups tend to sprout up in the shadow of great research institutions, but in New York, Weill Cornell Medical College, Columbia University Medical Center and the rest of the city's A-list outposts are in uptown Manhattan, not Brooklyn. That distance has limited BioBAT's efforts to attract entrepreneurs, the newspaper reports.

Meanwhile, on Manhattan's East Side, a much glitzier project has found some success. The Alexandria Center for Life Science, opened in 2010, snagged a major anchor tenant in 2012 when Roche ($RHHBY) decided to headquarter its U.S. early development operation there.

That site offers much closer proximity to the city's major research hubs, but, with rents around $80 a square foot, it largely caters to Big Pharma, not spendthrift startups, according to WSJ. BioBAT's rates, in the range of $30 to $40, are much more amenable to small companies, but the relative seclusion of Brooklyn makes it a tough sell.

But a group of local luminaries is working to help make New York's bio ecosystem less top-heavy. Under a public-private deal formed in the waning days of Michael Bloomberg's tenure, Celgene ($CELG) and Eli Lilly ($LLY) are teaming up with the city to help launch a $100 million program that aims to found up to 20 local biotechs, scouting for a venture partner to join the fold.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->